Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2026)

Tg Therapeutics' Cost of Revenue history runs 6 years deep, the most recent figure standing at $33.5 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 115.62% year-over-year to $33.5 million in Q1 2026; TTM through Mar 2026 was $118.7 million, a 144.28% increase from a year earlier, with the FY2025 full-year figure at $100.7 million, up 161.69% from the prior year.
• Cost of Revenue fell to $33.5 million in Q1 2026 per TGTX's latest filing, from $38.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $38.1 million in Q4 2025 and bottomed at $2000.0 in Q3 2022.
• The 5-year median for Cost of Revenue is $8.3 million (2024), against an average of $12.5 million.
• Across the five-year window, Cost of Revenue jumped 261700.0% in 2023 and jumped 96.07% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $3000.0 in 2022, then soared by 261700.0% to $7.9 million in 2023, then soared by 96.07% to $15.4 million in 2024, then soared by 147.69% to $38.1 million in 2025, then fell by 12.14% to $33.5 million in 2026.
• Per Business Quant, the three latest TGTX Cost of Revenue figures stand at $33.5 million (Q1 2026), $38.1 million (Q4 2025), and $28.1 million (Q3 2025).